BEGIN:VCALENDAR VERSION:2.0 METHOD:PUBLISH PRODID:-//Telerik Inc.//Sitefinity CMS 13.3//EN BEGIN:VEVENT DESCRIPTION:This 1-day scientific meeting will provide an update on latest trends in HTA\, including: the Real-World Evidence Navigator tool created by the IMI GetReal project\; the EUnetHTA Joint Action 3 initiative and me thodology being researched\; introduction to value-based frameworks and es timands in HTA. \; Patient perspectives in HTA will be discussed inclu ding how to involve patients in HTA and latest methods in patient reported outcomes. \; HTA related methodological considerations will be highli ghted including approaches to handle treatment switching in HTA. \; In dustry HTA case studies will also be presented. \; Speakers include we ll known representatives from academia\, European regulatory bodies and in dustry. The day will end with a panel discussion. \nTo download the flyer please click here. Outline of the Agenda  \;09:30 Welcome Chrissi e Fletcher (Amgen\, Chair HTA SIG)\, William Malbecq (MSD)\n &n bsp\;  \;09:50 Session: Trends in HTA(1) Introducing the RWE Naviga tor \;- \;Heather Stegenga (NICE) EUnetHTA Joint Action 3 activit ies \;- Zoe Garrett (NICE)  \;11:10 Coffee Break  \;11:30 Session: HTA research and methods Adjusting for treatment switching in r andomised controlled trials \;- Nick Latimer (University of Sheffield) Accumulated Industry experience in bridging regulatory and HTA \;re search methodologies \;- \;William Malbecq\, Kristel Vandormael (M SD)  \;12:50  \;Lunch  \;13:30 Session: Patient perspecti ves in HTA Involving the patient in HTA \;- \;Karen Facey (Eviden ce Based Health Policy Consultant) Benefit-risk Assessment in HTA \; - \;Shahrul Mt-Isa (MSD)\, Susan Talbot (Amgen)  \;14:50 Coffee Break  \;15:10 Session: Trends in HTA(2) Value-based frameworks&n bsp\;- \;Jan McKendrick (PRMA Consulting) Estimands in HTA- \;Jas on Wang (Celgene)\, \;Chrissie Fletcher (Amgen)  \;16:30 Panel Discussion  \;17:00 Summary and meeting close Registration \nF ee includes lunch &\; refreshments. Registration on or before 14th October PSI Member  \;£\;100 (plus VAT) Non-Member  \;&po und\;140 \;(plus VAT) Academic  \;£\;70 (plus VAT) Regis tration after 14th October PSI Member  \;£\;120 (plus VAT) No n-Member  \;£\;160 (plus VAT) Academic  \;£\;90 (plus VAT) \nRegistration is now closed. DTEND;VALUE=DATE:20171129 DTSTAMP:20240328T142151Z DTSTART;VALUE=DATE:20171128 LOCATION:N1C 4AG\,London\,Two Pancras Square\,MSD SEQUENCE:0 SUMMARY:European Statistical Meeting: Latest Trends in Health Technology As sessments UID:RFCALITEM638472325118622448 X-ALT-DESC;FMTTYPE=text/html:
This 1-day scientific meeting will provide an update on latest trends in HTA\, including: the Real-World Evidence Nav igator tool created by the IMI GetReal project\; the EUnetHTA Joint Action 3 initiative and methodology being researched\; introduction to value-bas ed frameworks and estimands in HTA. \; Patient perspectives in HTA wil l be discussed including how to involve patients in HTA and latest methods in patient reported outcomes. \; HTA related methodological considera tions will be highlighted including approaches to handle treatment switchi ng in HTA. \; Industry HTA case studies will also be presented. \;
Speakers include well known representatives from academia\, Europe
an regulatory bodies and industry. The day will end with a panel discussio
n.
\nTo download the flyer please click here.
 \;09:30 | Welcome Chrissie Fletcher (A mgen\, Chair HTA SIG)\, William Malbecq (MSD) \n  \; td> |
 \;09:50 | Session: Trends in HTA(1)
Introducing the RWE Navigator& nbsp\;- \;Heather Stegenga (NICE) EUnetHTA Joint Action 3 activities \;- Zoe Garrett (NICE) < /em> |
 \;11:10 | Coffee Break |
 \;11:30 | Session: HTA research
and methods Adjusting for treatment switching in randomised controlled trials \;- Nick Latimer (University of Sheffield) Acc
umulated Industry experience in bridging regulatory and HTA \;rese
arch methodologies \;- \;William Malbecq\, Kristel Vandor
mael (MSD) |
 \;12:50 | &nbs p\;Lunch |
 \;13:30 | Involving the patient in HTA \;-&nbs p\;Karen Facey (Evidence Based Health Policy Consultant) Benefit-risk Assessment in HTA \;- \;Shahru
l Mt-Isa (MSD)\, Susan Talbot (Amgen) |
&nbs p\;14:50 | Coffee Break |
 \;15:10 | Session: Trends in HTA(2) Value-based frameworks \;- \;Jan McKendri ck (PRMA Consulting) Estimands in HTA- \;Jason Wan g (Celgene)\, \;Chrissie Fletcher (Amgen) |
 \;16:30 | Panel Discussion | tr>
 \;17:00 | Summary and meeting close |
Registration on or before 14th Octo ber | |
PSI Member |  \;£\;100 (plus VAT) |
Non-Member td> |  \;£\;140 \;(plu
s VAT) |
Academic |  \;£\;70 (plus VAT) |
Registration after 14th October | |
PSI Member |  \;£ \;120 (plus VAT) |
Non-Member |  \;£\;160 (plus VAT) |
Academic |  \;£\;90 (plus VAT) |